112 related articles for article (PubMed ID: 11142629)
1. HIV immunotherapeutic vaccines.
Peters BS
Antivir Chem Chemother; 2000 Sep; 11(5):311-20. PubMed ID: 11142629
[TBL] [Abstract][Full Text] [Related]
2. The basis for HIV immunotherapeutic vaccines.
Peters BS
Vaccine; 2001 Dec; 20(5-6):688-705. PubMed ID: 11738732
[TBL] [Abstract][Full Text] [Related]
3. Improving HIV-specific immune responses in HIV-infected patients.
Hardy GA; Imami N; Gotch FM
J HIV Ther; 2002 May; 7(2):40-5. PubMed ID: 12553687
[TBL] [Abstract][Full Text] [Related]
4. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
[TBL] [Abstract][Full Text] [Related]
5. Remune trials recruiting.
PI Perspect; 1996 Sep; (No 19):17. PubMed ID: 11363901
[TBL] [Abstract][Full Text] [Related]
6. Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
Chantratita W; Sukeepaisarncharoen W; Chandeying V; Kulpradist S; Israngkura Na Ayudhtaya B; Rugpao S; Sirawaraporn W; Boonshuyar C; Churdboonchart V
HIV Med; 2004 Sep; 5(5):317-25. PubMed ID: 15369506
[TBL] [Abstract][Full Text] [Related]
7. [The quest for an HIV vaccine].
Girard MP
Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
[TBL] [Abstract][Full Text] [Related]
9. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
10. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
[TBL] [Abstract][Full Text] [Related]
11. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.
Myagkikh M; Alipanah S; Markham PD; Tartaglia J; Paoletti E; Gallo RC; Franchini G; Robert-Guroff M
AIDS Res Hum Retroviruses; 1996 Jul; 12(11):985-92. PubMed ID: 8827214
[TBL] [Abstract][Full Text] [Related]
12. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency.
Tsoukas CM; Raboud J; Bernard NF; Montaner JS; Gill MJ; Rachlis A; Fong IW; Schlech W; Djurdjev O; Freedman J; Thomas R; Lafrenière R; Wainberg MA; Cassol S; O'Shaughnessy M; Todd J; Volvovitz F; Smith GE
AIDS Res Hum Retroviruses; 1998 Apr; 14(6):483-90. PubMed ID: 9566550
[TBL] [Abstract][Full Text] [Related]
13. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
Gorse GJ; Simionescu RE; Patel GB
Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
[TBL] [Abstract][Full Text] [Related]
14. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
Román VR; Jensen KJ; Jensen SS; Leo-Hansen C; Jespersen S; da Silva Té D; Rodrigues CM; Janitzek CM; Vinner L; Katzenstein TL; Andersen P; Kromann I; Andreasen LV; Karlsson I; Fomsgaard A
AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1504-12. PubMed ID: 23634822
[TBL] [Abstract][Full Text] [Related]
17. Remune trial will stop; new trials planned.
James JS
AIDS Treat News; 1999 May; (No 319):1-2. PubMed ID: 11366461
[TBL] [Abstract][Full Text] [Related]
18. A boost for the immune system.
TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365925
[TBL] [Abstract][Full Text] [Related]
19. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
[TBL] [Abstract][Full Text] [Related]
20. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]